How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.

PubWeight™: 1.87‹?› | Rank: Top 3%

🔗 View Article (PMID 20043014)

Published in J Invest Dermatol on December 31, 2009


Phyllis I Spuls1, Lidian L A Lecluse, Marie-Louise N F Poulsen, Jan D Bos, Robert S Stern, Tamar Nijsten

Author Affiliations

1: Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. PH.I.SPULS@AMC.UVA.NL

Articles citing this

Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol (2012) 2.19

Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res (2010) 1.60

Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force. Value Health (2015) 1.59

Measuring disease activity in psoriatic arthritis. Int J Rheumatol (2012) 0.90

Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study. J Eur Acad Dermatol Venereol (2012) 0.90

Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. J Transl Med (2015) 0.81

Histopathological findings are associated with the clinical types of psoriasis but not with the corresponding lesional psoriasis severity index. Ann Dermatol (2015) 0.81

Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol (2013) 0.81

Bioelectrical phase angle and psoriasis: a novel association with psoriasis severity, quality of life and metabolic syndrome. J Transl Med (2016) 0.80

In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopy. Biomed Opt Express (2014) 0.79

Validation of psoriasis clinical severity and outcome measures: searching for a gold standard. Arch Dermatol (2010) 0.78

Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J Immunol Res (2014) 0.78

Clinical nonlinear laser imaging of human skin: a review. Biomed Res Int (2014) 0.77

Responsiveness to change and interpretability of the simplified psoriasis index. J Invest Dermatol (2013) 0.75

Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians. J Eur Acad Dermatol Venereol (2014) 0.75

Dyslipidemia in Psoriasis: A Case Controlled Study. Int Sch Res Notices (2014) 0.75

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial. PLoS One (2017) 0.75

Articles by these authors

Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc (2004) 3.40

Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04

Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol (2007) 2.59

Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 2.45

In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44

Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol (2010) 2.18

Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol (2006) 2.16

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12

Polidocanol concentration and time affect the properties of foam used for sclerotherapy. Dermatol Surg (2011) 2.03

Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95

Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol (2004) 1.94

Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol (2012) 1.93

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol (2002) 1.84

Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol (2007) 1.83

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Heat conduction from the exceedingly hot fiber tip contributes to the endovenous laser ablation of varicose veins. Lasers Med Sci (2009) 1.69

The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol (2005) 1.68

Impact of melanoma on patients' lives among 562 survivors: a Dutch population-based study. Arch Dermatol (2011) 1.66

Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol (2006) 1.62

Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol (2006) 1.57

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol (2007) 1.55

The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol (2003) 1.53

Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg (2008) 1.51

Proof-of-principle study of steam ablation as novel thermal therapy for saphenous varicose veins. J Vasc Surg (2011) 1.47

Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol (2005) 1.45

Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy. Melanoma Res (2009) 1.43

Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol (2010) 1.42

Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41

UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol (2005) 1.40

[Basal cell carcinoma: often more than one]. Ned Tijdschr Geneeskd (2011) 1.39

Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol (2013) 1.39

Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg (2006) 1.24

Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. J Invest Dermatol (2010) 1.24

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22

Endovenous laser ablation-induced complications: review of the literature and new cases. Dermatol Surg (2009) 1.17

Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol (2005) 1.16

Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14

Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol (2013) 1.13

Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol (2009) 1.11

MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09

Bullous pemphigoid therapy -- think globally, act locally. N Engl J Med (2002) 1.09

Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol (2012) 1.07

The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07

Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol (2011) 1.06

Overview of psoriasis. Dermatol Ther (2004) 1.04

Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J Invest Dermatol (2010) 1.04

Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer (2013) 1.02

Risk factors for single and multiple basal cell carcinomas. Arch Dermatol (2010) 1.01

Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol (2013) 0.99

Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol (2009) 0.98

Telaprevir-related dermatitis. JAMA Dermatol (2013) 0.98

Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. J Vasc Surg (2013) 0.98

Carbonized blood deposited on fibres during 810, 940 and 1,470 nm endovenous laser ablation: thickness and absorption by optical coherence tomography. Lasers Med Sci (2010) 0.97

Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol (2006) 0.97

The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol (2003) 0.97

Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study. J Invest Dermatol (2007) 0.96

Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol (2013) 0.95

Comprehensive candidate gene study highlights UGT1A and BNC2 as new genes determining continuous skin color variation in Europeans. Hum Genet (2012) 0.95

Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol (2005) 0.93

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92

Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res (2005) 0.91

Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.90

Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol (2011) 0.90

Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. JAMA Dermatol (2013) 0.90

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology (2002) 0.90

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89

T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-gamma expression. Arch Dermatol Res (2004) 0.89

The heat-pipe resembling action of boiling bubbles in endovenous laser ablation. Lasers Med Sci (2010) 0.89

Reactive oxygen species and melanoma: an explanation for gender differences in survival? Pigment Cell Melanoma Res (2010) 0.89

Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol (2003) 0.89

The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc (2004) 0.89

High-ceiling diuretics are associated with an increased risk of basal cell carcinoma in a population-based follow-up study. Eur J Cancer (2010) 0.89

Duplication of the great saphenous vein: a definition problem and implications for therapy. Dermatol Surg (2011) 0.89

Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res (2004) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Optical-thermal mathematical model for endovenous laser ablation of varicose veins. Lasers Med Sci (2013) 0.87

Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol (2008) 0.87

Etanercept: an overview of dermatologic adverse events. Arch Dermatol (2011) 0.87

The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol (2009) 0.86

Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol (2011) 0.86

Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol (2004) 0.86

Expression of terminal complement components by human keratinocytes. Mol Immunol (2007) 0.85

High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol (2005) 0.85

Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. Acta Derm Venereol (2009) 0.84

Personality is associated with health status and impact of cancer among melanoma survivors. Eur J Cancer (2009) 0.84

Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol (2007) 0.83

Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol (2002) 0.83

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83

Dimensionality of the dermatology life quality index (DLQI): a commentary. Acta Derm Venereol (2006) 0.83

Socio-economic implications of cancer survivorship: results from the PROFILES registry. Eur J Cancer (2011) 0.83

Patient advocacy groups: let's stick together. J Invest Dermatol (2010) 0.83